Thierry De Baère (Gustave Roussy; Villejuif, France) talks to Interventional News about the rationale behind setting up the Initiative on Superselective Conventional Transarterial Chemoembolization (INSPIRE), which aims to bring Asian and European experts together in order to collaborate on standardising cTACE across the globe.
Speaking at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) annual meeting (10–14 September 2022, Barcelona, Spain), De Baère discusses whether or not TACE/cTACE will remain a choice for hepatocellular carcinoma (HCC) patients in the future. “I think cTACE will survive only in very select populations,” he says.
De Baère concludes by highlighting why it is important to improve cTACE, before outlining how he hopes the paper will impact the interventional radiology community.
This video is sponsored by Guerbet.